Quest Diagnostics said on April 27, 2026 it priced a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036 under its shelf registration statement.

1. 01

   Quest Diagnostics said on April 27, 2026 it priced a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036 under its shelf registration statement.

2. 02

   The company said it expects to receive the net proceeds upon closing on May 6, 2026, subject to the satisfaction of customary closing conditions, and intends to use the net proceeds for general corporate purposes, which may include the repayment of indebtedness.

3. 03

   Quest Diagnostics said the indebtedness it may repay includes $500 million aggregate principal amount of 3.45% Senior Notes that mature on June 1, 2026.

4. 04

   The company said on April 27, 2026 it entered into an underwriting agreement with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Mizuho Securities USA LLC on behalf of themselves and the other underwriters named therein.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.